Patents by Inventor David S. Baker

David S. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393649
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 23, 2021
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20210283142
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 16, 2021
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20210213008
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 7, 2019
    Publication date: July 15, 2021
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Patent number: 11052095
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 6, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 11052094
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 6, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 10953002
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: March 23, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Patent number: 10940145
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: March 9, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Publication number: 20210059998
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 4, 2021
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Patent number: 10888557
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: January 12, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Patent number: 10864208
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 15, 2020
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 10842787
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: November 24, 2020
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Publication number: 20200345542
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 21, 2018
    Publication date: November 5, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20200338060
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 29, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Patent number: 10813923
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: October 27, 2020
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Publication number: 20200316052
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthamic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20200306239
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: October 1, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20200297712
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 24, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20200297713
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 24, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun Takruri
  • Publication number: 20200297714
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 24, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun Takruri
  • Publication number: 20200197410
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER